Synairgen (GB:SNG) has released an update.
Synairgen plc, a UK-based respiratory drug development company, has announced the successful passing of all resolutions at its Annual General Meeting and the appointment of Dr. Mark Parry-Billings as the new Chairman of the Board. Dr. Parry-Billings brings over 30 years of experience in biotech and pharmaceuticals, specializing in respiratory therapeutics. The company is focused on advancing SNG001, an inhaled antiviral treatment for severe viral lung infections, with no current approved antiviral therapies for most patients.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.
